Literature DB >> 28526800

Antacid use and subclinical interstitial lung disease: the MESA study.

Michaela D Restivo1, Anna Podolanczuk1, Steven M Kawut2, Ganesh Raghu3, Peter Leary3, R Graham Barr1,4, David J Lederer5,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28526800      PMCID： PMC5532532          DOI： 10.1183/13993003.02566-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  15 in total

1.  Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.

Authors:  Michael Kreuter; Wim Wuyts; Elisabetta Renzoni; Dirk Koschel; Toby M Maher; Martin Kolb; Derek Weycker; Paolo Spagnolo; Klaus-Uwe Kirchgaessler; Felix J F Herth; Ulrich Costabel
Journal:  Lancet Respir Med       Date:  2016-03-31       Impact factor: 30.700

2.  Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.

Authors:  Joyce S Lee; Jay H Ryu; Brett M Elicker; Carmen P Lydell; Kirk D Jones; Paul J Wolters; Talmadge E King; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2011-06-23       Impact factor: 21.405

3.  High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study.

Authors:  Anna J Podolanczuk; Elizabeth C Oelsner; R Graham Barr; Eric A Hoffman; Hilary F Armstrong; John H M Austin; Robert C Basner; Matthew N Bartels; Jason D Christie; Paul L Enright; Bernadette R Gochuico; Karen Hinckley Stukovsky; Joel D Kaufman; P Hrudaya Nath; John D Newell; Scott M Palmer; Dan Rabinowitz; Ganesh Raghu; Jessica L Sell; Jered Sieren; Sushil K Sonavane; Russell P Tracy; Jubal R Watts; Kayleen Williams; Steven M Kawut; David J Lederer
Journal:  Eur Respir J       Date:  2016-07-28       Impact factor: 16.671

4.  Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  J S Lee; J W Song; P J Wolters; B M Elicker; T E King; D S Kim; H R Collard
Journal:  Eur Respir J       Date:  2011-12-19       Impact factor: 16.671

Review 5.  Idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Annie Pardo; Moisés Selman
Journal:  Lancet       Date:  2011-06-28       Impact factor: 79.321

6.  Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells.

Authors:  Jan C Becker; Nina Grosser; Christian Waltke; Stephanie Schulz; Kati Erdmann; Wolfram Domschke; Henning Schröder; Thorsten Pohle
Journal:  Biochem Biophys Res Commun       Date:  2006-05-06       Impact factor: 3.575

7.  Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients.

Authors:  Edoardo Savarino; Roberto Carbone; Elisa Marabotto; Manuele Furnari; Luca Sconfienza; Massimo Ghio; Patrizia Zentilin; Vincenzo Savarino
Journal:  Eur Respir J       Date:  2013-03-07       Impact factor: 16.671

8.  Multi-Ethnic Study of Atherosclerosis: objectives and design.

Authors:  Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

9.  Lung volumes and emphysema in smokers with interstitial lung abnormalities.

Authors:  George R Washko; Gary M Hunninghake; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; James C Ross; Raúl San José Estépar; David A Lynch; John M Brehm; Katherine P Andriole; Alejandro A Diaz; Ramin Khorasani; Katherine D'Aco; Frank C Sciurba; Edwin K Silverman; Hiroto Hatabu; Ivan O Rosas
Journal:  N Engl J Med       Date:  2011-03-10       Impact factor: 91.245

10.  Anti-inflammatory and anti-oxidative properties of proton pump inhibitors.

Authors:  Yuji Naito
Journal:  J Clin Biochem Nutr       Date:  2007-09       Impact factor: 3.114
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.